Clinical Trial Update: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating TVB-2640 in combination with trastuzumab and paclitaxel or endocrine therapy for HER2-positive metastatic breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Endocrine therapy
• PACLITAXEL (PACLITAXEL)
• TVB-2640
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-24